Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
|Date:||Wednesday, December 12, 2018|
|Time:||2:20 p.m. Eastern Standard Time|
|Location:||Mandarin Oriental New York, New York|
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com, under the “Investor & News” section.
Osmotica has a late‑stage development pipeline highlighted by two NDA candidates in Phase III clinical trials: arbaclofen extended‑release tablets for muscle spasticity in multiple sclerosis patients and RVL‑1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for the treatment of blepharoptosis, or droopy eyelid.
Osmotica has operations in
Investor and Media Relations for
In-Site Communications, Inc.
Source: Osmotica Holdings US LLC